W hen parents or guardians choose to administer derivatives of marijuana to their child as a treatment for a medical condition or to alleviate symptoms, school nurses encounter both a legal and an ethical dilemma. While all states, with the exception of Idaho, Nebraska, and South Dakota allow the legal use of certain marijuana derivatives, marijuana remains a Schedule 1 substance under federal law since 1970 (National Conference of State Legislators [NCSL] , 2019). A Schedule 1 designation means that the substance has a high abuse potential and no accepted medical uses and that even with medical supervision there is a lack of accepted safety (NCSL, 2019) .
Both the American Academy of Pediatrics (AAP) and the National Association of School Nurses (NASN) have taken similar positions on the use of medical marijuana (MM) in children. In its 2015 position statement, AAP opposes MM in children with the exception of cannabis derivatives approved by the U.S. Food and Drug Administration (FDA) . AAP also recognizes that compassionate use for children "may be an option for children who have life-limiting or severely debilitating conditions and for whom current therapies are inadequate" (Ammerman, Ryan, & Adelman, 2015, p. e779) .
NASN issued its first position brief that addresses MM at school in January 2019 and offers this guidance: "It is the position of the National Association of School Nurses (NASN) that only FDA approved cannabis/marijuana medications be allowed in the school setting" (p. 1). NASN in its position brief does provide additional guidance for school nurses caring for students under the influence of MM while attending school. (Refer to Figure 1 toward the end of this article). The purpose of this article is to inform school nurses regarding the legal, ethical, and practical considerations while caring for students under the influence of MM during the school day.
Background
While Schedule I of the federal Controlled Substances Act designation severely restricts marijuana's use in research trials (The National Academies of Sciences, Engineering, and Medicine [NASEM], 2017), states proceed to pass legislation to legalize medicinal and recreational use (NCSL, 2019) . According to the National School Boards Association (2019), a school may restrict use of MM on school property due to its federal designation as an illegal substance, mandate to maintain a drugfree workplace, or the risk, if prosecuted, of federal funding loss.
Since MM is not regulated by the FDA or prescribed by a physician, caregivers must determine dosage from anecdotal evidence or by trial and error (Byars, Theisen, & Bolton, 2019) . It is important to note that preparations obtained from private unregulated sources may vary widely from the package label. In one research letter published in JAMA Journal of the American Medical Association, the (Vandrey et al., 2015) . Some states do regulate medical dispensaries to control for quality and label accuracy, but this is not true of all states that allow the possession of MM (NCSL, 2019) .
The variety of names associated with MM add to the confusion already caused by conflicting federal and state law. Cannabis is the proper name of the marijuana plant and Cannabis sativa and Cannabis indica are the two species of cannabis most often referenced (NASEM, 2017) . Dependent on the desired effect, different parts of the plant are used to obtain the highest concentrations of the most recognized cannabinoids THC (tetrahydrocannabinol) and CBD (cannabidiol).
THC is known for the "high" it produces and is grown primarily for recreational and medicinal use. THC is most concentrated in the female flower. CBD does not produce recreational effects, and its concentration is highest in the leaves and stem (NASEM, 2017) . Selective breeding has produced plants that are higher in THC or CBD based on the desired effect and purpose. It is erroneous to associate one variety of cannabis with a particular concentration of THC or CBD, since wide variances exist within both the indica and sativa species (Sawler et al., 2015) .
By legal definition, hemp is low in THC and high in CBD (Sawler et al., 2015) . In January 2019, the Agriculture Improvement Act (AIA) of 2018 legalized the cultivation and sale of hemp (See Photo 1). AIA defines hemp as the plant Cannabis sativa L. and any part of the plant with a delta-9 THC concentration of not more than 0.3% by dry weight. While AIA defines Cannabis sativa L. as hemp, this is despite the fact that hemp has a greater proportion of alleles that align with Cannabis indica (Sawler et al., 2015) .
It is important to note that AIA preserves the FDA's current authority to regulate products containing cannabis or cannabis-derived compounds under the Federal Food, Drug, and Cosmetic Act and Section 351 of the Public Health Service Act (FDA, 2018) . The only hemp products approved by the FDA as safe for human consumption are hulled hemp seeds, hemp seed protein, and hemp seed oil. None of these three products contain CBD or THC, making them safe to consume. CBD remains illegal and is not approved to be added to foods or products that make medical or therapeutic claims. Hemp products, though legal, cannot make any disease treatment claims (FDA, 2018) . This means that any hemp product that makes disease treatment claims is doing so in violation of federal law.
The only marijuana-derived product that is FDA approved is Epidiolex. It is categorized as a Schedule V substance and contains pure CBD. It is approved for the treatment of Dravet and Lennox-Gasteau seizure disorders. Prior to approval, Epidiolex went through rigorous clinical trials (Devinsky et al., 2016; Devinsky et al., 2017) . Epidiolex appears to exert its anticonvulsive effects without using the body's cannabinoid receptors. Commonly reported side effects include somnolence; decreased appetite; diarrhea; transaminase elevations; fatigue, malaise, and asthenia; rash; insomnia, sleep disorder, and poor quality of sleep; and infections (Lazaridis, Eraikhuemen, Williams, & Lovince, 2019) . Epidiolex may be legally administered at school because of its FDA approval and Schedule V designation.
Mechanism of Action
To understand how cannabis binds and activates receptors within the human body involves a simplified explanation of the endocannabidiol system (ECS). The human body produces its own (endogenous) cannabinoids, the only known retrograde synaptic neurotransmitters. The ECS is made up of these endocannabinoids, their receptors, Photo 1. Text From the Agriculture Improvement Act of 2018, Framed by Actual Hemp Leaves and the associated mediating enzymes for synthesis and degradation. A central regulatory system, the ECS functions to maintain homeostasis for metabolic functions, such as neurotransmitter, inflammation, and energy modulation (Jarvis, Rassmussen, & Winters, 2017) .
There are two known primary receptor types labeled CB1 and CB2. CB1 receptors are widely expressed in the hippocampus, basal ganglia, amygdala, cortical areas, and cerebellum regions of the brain that are associated with mood, cognition, and motor control. CB1 receptors have also been found to a lesser degree in other locations such as the intestine, liver, adipose tissue, and immune cells (Bonini et al., 2018) . CB2 receptors are found in the spleen, tonsils, select white blood cells, peripheral blood mononuclear cells, thymus, pancreas, lung, and reproductive tissues. CB2 receptors are also found in the microglia of the brain, and all are primarily involved in the immune system response (Turcotte, Blanchet, Laviolette, & Flamand, 2016) .
A cannabinoid is a chemical that signals receptor cells to affect the release of neurotransmitters. These can be produced by the body (endocannabinoids), plant sources (phytocannabinoids), or synthetic sources (Byars et al., 2019) . Endocannabinoids are produced when needed, not stored (Clark, 2018) . Both THC and CBD are classified as phytocannabinoids. Synthetic sources of cannabinoids may be legal and FDA approved, such as Marinol, which is synthetic THC, or illegal such as Spice or K2. While THC from plant sources is a partial agonist at CB1 receptors, many synthetic compounds are full agonists and are dramatically more potent, leading to more intense psychoactive and physical effects including toxicity and death. Symptoms most often observed included agitation, altered level of consciousness, and dilated pupils (Baum, Bailey, Chan, & Blumenschein, 2017) .
Research Regarding Cannabis
Evidence to support pediatric use of cannabis is strongest for the treatment of chemotherapy-induced nausea and vomiting with increasing evidence demonstrating benefit for intractable epilepsy. At this time, there is insufficient evidence to support use for spasticity, neuropathic pain, posttraumatic stress disorder, and Tourette syndrome (Wong & Wilens, 2017) . It is important to note that there is substantial evidence in adult populations to support cannabis use for chronic pain (NASEM, 2017) .
With growing public acceptance of cannabis use at the state level, more research is needed to advise use in pediatric populations. Feasibility studies, such as the one that demonstrates improvement with severe behavioral problems often associated with autism in youth, are now available on the internet (Aran, Cassuto, Lubotzky, Wattad, & Hazan, 2018) . Without Federal regulation of MM or medical prescription, the challenges associated with cannabis use in pediatric practice are immeasurable.
Although the focus of this article is to provide guidance regarding the pediatric use of cannabis, children and youth may experience accidental exposure to an adult's supply of recreational or MM. School nurses should be aware that "there is moderate evidence of a statistical association between cannabis use and increased risk of overdose injuries, including respiratory distress, among pediatric populations in U.S. states where cannabis is legal" (NASEM, 2017, p. 236 ). This finding is in opposition to the commonly held belief that it is impossible to overdose with marijuana use.
Implications for School Nursing Practice
Leadership, Care Coordination, Quality Improvement, Community/Public Health, and Standards of Practice are the five principles of the 21st Century Framework for School Nursing Practice (NASN, 2016) . When providing care for a student who is administered MM, two of the principles are particularly valuable: Standards of Practice and Care Coordination. In this section, these two principles are further broken down into practice components while discussing the implications for managing MM at school.
While challenging to refuse a parental request to administer MM at school, NASN bases its Cannabis/Marijuana position brief on sound evidence described in its rationale section (NASN, 2019) . Our Professional Standards of Practice dictate that our interventions be evidence based. Having participated in special education meetings where this request was made, it is imperative that school nurses continue to support the family and the choices they have made. While some states such as Maine and Illinois (NCSL, 2019) allow parents to administer MM on school grounds, other states do not, and parents must administer at home. Declining to administer MM at school is not in conflict with supporting parents and guardians or the Care Coordination principle. It is the school nurse who can collaborate with school administrators and the district's attorney to address requests for MM administration during the school day or suggest supportive school accommodations to lessen family burden.
As recommended in the NASN Cannabis/Marijuana position brief, the school nurse should become familiar with the effects and potential side effects of MM administered to better monitor student response. Knowledge regarding your state MM laws should be updated with each legislative session as these are fast-changing laws. Ask the parent or guardian for timely notification when the preparation or MM dosage changes at home, as this may affect the student's behavior at school. If the student has a behavioral goal on their individualized education plan, it is important for the school nurse to notify the special education teacher as these changes may affect the application of data collected. Such interdisciplinary teaming is a valuable part of Care Coordination. Staff should also be trained to report any unusual student observations directly to the school nurse. It is the school nurse who then can conduct any additional observations and report these to the parent and primary care provider.
School nurse should not hesitate to include MM monitoring in a student's individualized healthcare plan. Nursing diagnoses are based on the indications for MM use such as pain or seizure 1
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Position Brief
Summary Cannabis continues to be classified federally as a Schedule I Controlled Substance (Drug Enforcement Administration [DEA], n.d.); however, with growing cultural acceptance of cannabis, increasing numbers of states have legalized medical and/or recreational usage (National Conference of State Legislatures [NCSL], 2017) . This contradiction between federal and state laws has created uncertainty for the school nurse when cannabis products are brought into the school setting for administration to students.
Therefore: it is the position of the National Association of School Nurses (NASN) that only FDA approved cannabis/marijuana medications be allowed in the school setting.
In addition, NASN recommends that school nurses should be knowledgeable in the following principles, which create a foundation for safe and informed nursing care of patients using medical or recreational cannabis (adapted from National Council of State Boards of Nursing (NCSBN) Guidelines for the Nursing Care of Patients Using Marijuana, 2018):
1. The school nurse shall have a working knowledge of the current state of legalization of medical and recreational cannabis use in the state/jurisdiction in which they practice. 2. The school nurse shall have a working knowledge of their state/jurisdiction's medical marijuana program, if applicable. 3. The school nurse shall have an understanding of the endocannabinoid system, cannabinoid receptors, cannabinoids, and the interactions between them. 4. The school nurse shall have an understanding of cannabis pharmacology and the research associated with the medical use of cannabis, and any Federal Drug Administration (FDA) approved cannabis-type medications. 5. The school nurse shall be able to identify the safety considerations for patient use of cannabis as it relates to the school setting. 6. The school nurse shall approach the student and family without judgment regarding their choice of treatment or preferences.
Rationale
The NCSBN has provided guidance for nurses across the country regarding the administration of cannabis in a professional setting. School nurses can also benefit from this guidance (NCSBN, 2018 with the certifying physician and any outside agencies involved with care and providing factual information to educational staff regarding the use of MM in your state. An example of associated expected outcomes then could focus on the reason for MM administration such as improved comfort resulting in better attendance or perhaps less class time lost to seizure activity.
Conclusion
The NASN position brief Cannabis/ Marijuana recommends that school nurses 2  Research on the efficacy of cannabis for treatment of certain medical conditions is limited and lacking, specifically related to indications, dosage, route, safety, adverse effects, and long-term effects of cannabis (NCSBN, 2018) .  There are limited studies that might show some efficacy for a narrow range of symptoms.
Without evidence that is scientifically rigorous, reportable, and based upon the student population, safe administration of cannabis has not been established for use in the school setting (NCSBN, 2018) .  School nurses must be well-informed about cannabis and how it affects the body, so safe nursing care can be provided at school.  The school nurse must work closely with parents who are using cannabis-based products for their children, so that appropriate planning and care coordination may occur, as based on the foundation of the 21st Century Framework for School Nursing Practice (NASN, 2016).
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